24 h of age was 0.830. At the cutoff BNP levels of 200 and 900 pg/ml at 24 h of age, sensitivity was 83.9 and 54.8% and specificity was 61.9 and 95.2%, respectively. Conclusions: BNP levels at 24 h of age can be used as a guide for early targeted treatment of hsPDA and avoid the unnecessary use of cyclooxygenase inhibitors in ELBW infants.
Introduction
A hemodynamically significant patent ductus arteriosus (hsPDA) in extremely low birth weight (ELBW) infants is a common and an important problem associated with significant morbidity and mortality including: intraventricular hemorrhage, necrotizing enterocolitis and bronchopulmonary dysplasia [1] . Therefore, optimal management of a PDA is important for improving the clinical outcomes of ELBW infants.
Although a more expectant approach to PDA may be recommended [2, 3] , there have been reported few data on permissive strategies related to PDA. Sehgal et al. [5] found that echocardiographic markers have low sensitivity and specificity with regard to ductal significance in isolation [4] and concluded that a more comprehensive echocardioKey Words B-type natriuretic peptide ؒ Patent ductus arteriosus ؒ Preterm infant ؒ Predictable usefulness Abstract Background: Earlier and more accurate identification of a high-risk group of preterm infants that are likely to develop a hemodynamically significant patent ductus arteriosus (hsPDA) would allow specific targeting of early treatment and thus possibly minimize the morbidity and mortality associated with a PDA in extremely low birth weight (ELBW) infants. Objective: To investigate the predictability of B-type natriuretic peptide (BNP) for early targeted treatment of hsPDA in ELBW infants. Methods: 73 ELBW infants that underwent echocardiographic evaluation and plasma BNP measurement after birth were enrolled. 31 infants developed hsPDA (HsPDA group) and 42 infants did not develop hsPDA (nPDA group). Results: BNP levels of the HsPDA group were significantly higher than those of the nPDA group at 24 h of age (921 [318-2,133] vs. 152 [91-450] pg/ml) but not different at 12 h of age. BNP levels at 24 h of age were significantly correlated with the magnitudes of the ductal shunt but not at 12 h of age. The area under the receiver operator characteristic curve of BNP levels for prediction of hsPDA at graphic evaluation is needed for more accurate decision making in infants with an hsPDA. However, a comprehensive echocardiographic evaluation by skilled clinicians is difficult to be performed frequently in developing country and could make these tiny infants unstable.
Recently, it has been reported that early biological markers were valuable for differentiating hsPDA from insignificant PDA [6, 7] . The B-type natriuretic peptide (BNP) is one of the cardiac neurohormones released by the ventricles in response to increased wall stress and volume or pressure overload [8, 9] . We have previously shown that the rapid assay for measurements of BNP may be a useful diagnostic tool for the diagnosis of a symptomatic PDA in premature infants; the levels of BNP were found to be high in the presence of an hsPDA [10] . Moreover, serial BNP measurements may be of value in determining the clinical course of a PDA in preterm infants [10, 11] .
We also reported that a rapid BNP assay at 24 and 48 h of age allows prediction of the subsequent hsPDA in preterm infants ranging from 25 to 34 weeks of gestational age (GA) [12] . However, the preliminary report [12] included only a small number of ELBW infants and there were no data on infants before 24 h of age. Czernik et al. [13] also reported that BNP levels on the second day of life can be a good predictor of hsPDA in extremely premature infants ( ^ 28 weeks of GA). However, they did not measure the BNP level at the very early postnatal period (within 24 h of age) and did not show the exact timing of the changes in BNP measurements after birth. Therefore, data on the early changes in the BNP levels associated with the hemodynamic changes of a PDA in ELBW infants are needed to use as a guide for early targeted treatment of hsPDA.
The aim of this study was to investigate the predictable usefulness of plasma BNP levels at 12 and 24 h of age (prior to the onset of symptoms) as a guide for early targeted treatment of hsPDA in ELBW infants.
Methods

Study Population and Design
This study was done retrospectively by review medical records. Among 105 Korean infants that were admitted to the neonatal intensive care unit (NICU) at the Korea University Ansan Hospital from January 2004 to June 2011, 73 ELBW infants were enrolled in this study that underwent clinical and echocardiographic examinations for a PDA and more than 2 times plasma BNP measurement during the first few days after birth. Infants (n = 9) that received cyclooxygenase inhibitor prophylaxis within 24 h of age were excluded from this study. Babies (n = 2) that had complex congenital heart disease detected on the first echocardiography, those (n = 3) that died within first 24 h of birth, and those (n = 18) that did not have informed consent given by their parents were also excluded.
Of the 73 infants, 31 developed hsPDA (HsPDA group) and 42 infants did not develop hsPDA (nPDA group). The HsPDA group was divided into two subgroups according to the time of diagnosis of symptomatic PDA: the Early HsPDA subgroup (n = 14) had symptomatic PDA diagnosed and cyclooxygenase inhibitor treatment at between 24 and 48 h of age; the Late HsPDA subgroup (n = 17) had symptomatic PDA diagnosed and cyclooxygenase inhibitor treatment after 48 h of age. Infants in the nPDA group did not have symptomatic PDA diagnosed and cyclooxygenase inhibitor treatment.
At the time of the admission of ELBW infants to the NICU, we explained to their parent's serial measurement of BNP and echocardiography, and obtained written parental informed consent in all cases. The review of medical records and study design was approved by the Institutional Review Board at the Ansan Hospital.
Use of antenatal steroids was defined to complete one cycle of betamethasone before delivery and use of dopamine was defined to inject dopamine (5-10 to 20 g/kg/min) continuously in patients with hypotension (the lower limit of normal mean arterial pressure was regarded to corrected gestational age).
Echocardiographic Studies
An Acuson Cypress ultrasound machine (Acuson Corporation, Mountain Drive, Calif., USA) with a 7-MHz transducer incorporating color-flow, pulse-wave, and continuous-wave Doppler was used. A two-dimensional, color Doppler, and M-mode echocardiography were performed every day from the first day of age for the ELBW infants that fulfilled the study entry criteria. Echocardiographic parameters for the degree of PDA shunting and volume load included the diameter of the ductus arteriosus (DA), the ratio of the left atrium to aortic root diameter (LA/AO ratio) and the diastolic flow velocity of the left pulmonary artery (DFLPA). Additional information on the echocardiographic studies has been previously reported [10] . Throughout the study, the echocardiography was performed by one investigator that did not know the results of the BNP measurements.
Measurements of Plasma BNP
The BNP levels were always measured at 24 h of age and more than one time at 12 and/or 48 h of age before treatment with a cyclooxygenase inhibitor. The BNP levels were assessed using a commercial kit (Triage BNP test; Biosite Diagnostics, San Diego, Calif., USA) by a fluorescence immunoassay at the bed side. Whole blood 0.25 ml for the measurement of BNP was collected by arterial or venous access. The measurable range of BNP concentrations was 5-5,000 pg/ml. The estimated coefficient variation for the test is 9.2-11.4%.
Diagnosis and Management of hsPDA
The clinical diagnosis of hsPDA was based on the following features: (1) the presence of a systolic or continuous murmur, (2) a bounding pulse or a hyperactive precordial pulse, (3) difficulty in maintaining the blood pressure, i.e. hypotension (the lower limit of normal mean arterial pressure was regarded to corrected gestational age) without response to loading fluid and infusion of dopamine, (4) a worsening ventilator status, and (5) chest radiographic evidence, i.e. pulmonary congestion or cardiomegaly (a cardiothoracic ratio 1 60%) with increased pulmonary flow. Symptomatic PDA was defined as the presence of two of these five signs with the confirmation of a large left to right ductal flow by color-flow Doppler echocardiography [10] . The policy of management to PDA in our NICU was that cyclooxygenase inhibitor was administered intravenously after confirming the diagnosis of symptomatic PDA.
Statistical Analyses
Categorical data are presented as numbers (%), and continuous data as the mean 8 SD or median [25-75%]. The 2 or Fisher's exact test was used to compare categorical variables and the Student's t test, the paired t test, the Mann-Whitney's rank sum U test, or the Kruskal-Wallis one-way analysis of variance on ranks to compare continuous variables. Correlations between BNP levels and echocardiographic parameters were calculated by the Spearman rank correlation analysis. Receiver operator characteristic (ROC) analysis was performed to determine the discriminating power of using BNP with regard to the prediction of hsPDA in ELBW infants. Data were analyzed using SPSS 12.0 for Windows (SPSS Inc., Chicago, Ill., USA). p ! 0.05 was considered significant.
Results
Patient Characteristics
There were no significant differences in the GA, birth weight and other associated perinatal factors except for the Apgar score at 1 min between the nPDA group and the HsPDA group. The characteristics of these two groups are shown in table 1 . Of 14 infants of the Early HsPDA subgroup, ductus arteriosus closed in 11 after one cycle of cyclooxygenase inhibitor and 3 infants needed additional treatment: second cycle of cyclooxygenase inhibitor (1 infant) or ligation (2 infants). Of 17 infants of the Late HsPDA subgroup, the ductus arteriosus closed in 11 infants and 6 infants needed additional treatment: second cycle of cyclooxygenase inhibitor (2 infants) or ligation (4 infants). 
Comparison of BNP Levels between the nPDA and HsPDA Groups
Comparison of the BNP Levels in the HsPDA Group over Time
In 27 infants of the HsPDA group who underwent plasma BNP measurement at 12 h of age, the BNP levels were significantly increased at 24 h of age (272 vs. 900 [297-1,448] pg/ml, p = 0.049).
Among the 27 infants, 12 infants (Early HsPDA subgroup) that had cyclooxygenase inhibitor treatment between 24 and 48 h of age had a trend of increasing BNP levels from 12 h of age (1,470 8 2,070 pg/ml) to 24 h of age (2,264 8 1,380 pg/ml); however, these differences were not statistically significant (p = 0.055). Fifteen infants (Late HsPDA subgroup) that had findings of symptomatic PDA after 48 h of age had no significant difference between BNP levels at 12 and 24 h of age (477 8 554 vs. 402 8 301 pg/ml, p = 0.483).
There was a significant difference in the BNP levels between the Early HsPDA subgroup (n = 14, 1,964 [1, ,250] pg/ml) and the Late HsPDA subgroup (n = 17, 384 [190-604] pg/ml) at 24 h of age (p ! 0.001). The BNP levels of the Late HsPDA subgroup were significantly increased from 24 to 48 h of age (n = 14, 513 8 584 vs. 2,389 8 1,544 pg/ml, p ! 0.001). 
Correlation between the BNP Levels and Magnitude of the Ductal Shunt by Echocardiography
There was poor correlation between the BNP levels at 12 h of age with the magnitude of the ductal shunt, such as the diameter of DA (r = 0.214, p = 0.193), the LA/AO (r = 0.351, p = 0.243) and the DFLPA (r = 0.428, p = 0.148). However, the BNP levels at 24 h of age were more correlated with the magnitude of the ductal shunt, such as the diameter of the DA (r = 0.474, p = 0.069), the LA/AO (r = 0.478, p = 0.049) and the DFLPA (r = 0.575, p = 0.031) than those at 12 h of age.
Association between the BNP Levels and Prediction of hsPDA in ELBW Infants
The area under the ROC curve for the prediction of hsPDA at 24 h of age was 0.830 (95% CI 0.723-0.938; p ! 0.001) ( fig. 1 ) . The ROC curve analysis confirmed that a value 1 864 pg/ml at 24 h was the best cut off BNP value for predicting subsequent hsPDA in the ELBW infants. At this cutoff level, the sensitivity was 54.8% (17 of 31), the specificity was 95.2% (40 of 42), positive predictive value was 89.5% (17 of 19), and negative predictive value 74.1% (40 of 54). Table 2 lists sensitivities, specificities, positive and negative predictive values for various changes in plasma BNP levels at 24 h of age.
Discussion
In this study, the BNP level at 12 h of age was not different between the HsPDA and nPDA groups. However, it was significantly different between the two groups at 24 h of age. An increase in the BNP level in the Early HsPDA subgroup and Late HsPDA subgroup was observed as the PDA became significant.
Da Graca et al. [14] showed that higher BNP levels correlated with an increasing grade of the PDA in preterm infants and suggested that co-morbidities may be more relevant for explaining the varying changes in the BNP levels than the GA. Flynn et al [15] reported that BNP levels correlate with the magnitude of the PDA in premature newborns, particularly more than 2 days of age and may be useful in guiding diagnostic and management strategies. Although, these studies [10, 14, 15] support the findings from this report, they did not evaluate the BNP for its ability to predict a hsPDA in preterm infants.
Compared to prior studies [12, 13] , this investigation adds to the literature the BNP levels during the very early postnatal period (within 24 h of age). The exact timing of the measurement of BNP levels in a relatively homogenous study population is reported.
The positive correlation between magnitude of ductal shunt by echocardiography and BNP levels has been reported [16] [17] [18] . We investigated the correlation between magnitude of ductal shunt and BNP levels at 12 and 24 h of age separately and could find that the BNP levels at 24 h of age have a higher correlation with magnitude of ductal shunt than BNP levels at 12 h of age.
Plasma BNP had a sensitivity of 83.9%, specificity of 61.9% at a cutoff value of 200 pg/ml and a sensitivity of 54.8%, specificity of 95.2% at a cutoff value of 900 pg/ml at 24 h of age in this study. If a cutoff level 1 200 pg/ml If a cutoff level 1 900 pg/ml at 24 h of age was used, 54.8% (17/31) of infants in the HsPDA group would identify for early targeted treatment of a hsPDA and most of the infants (40/42) in the nPDA group could avoid unnecessary treatment with cyclooxygenase inhibitors.
In conclusion, BNP measurements were useful for the prediction of subsequent hsPDA in ELBW infants at 24 h but not 12 h of age. At 24 h of age, a BNP level above 900 pg/ml can be used as a guide for early targeted treatment of hsPDA and avoid the unnecessary use of cyclooxygenase inhibitors in some ELBW infants.
